Atossa Therapeutics, Inc. (ATOS)
1.595
-0.16
(-8.86%)
USD |
NASDAQ |
Nov 20, 16:00
1.62
+0.02
(+1.57%)
After-Hours: 20:00
Atossa Therapeutics Enterprise Value : -4.767M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | -4.767M |
| November 19, 2026 | -3.220M |
| November 18, 2026 | -2.622M |
| November 17, 2026 | -1.723M |
| November 16, 2026 | -1.424M |
| November 13, 2026 | -1.125M |
| November 12, 2026 | -1.324M |
| November 11, 2026 | -0.426M |
| November 10, 2026 | 0.6717M |
| November 09, 2026 | 0.5719M |
| November 06, 2026 | 0.4721M |
| November 05, 2026 | -0.5258M |
| November 04, 2026 | 0.4721M |
| November 03, 2026 | 2.568M |
| November 02, 2026 | 2.268M |
| October 30, 2026 | 0.9711M |
| October 29, 2026 | 1.570M |
| October 28, 2026 | 2.967M |
| October 27, 2026 | 3.067M |
| October 26, 2026 | 3.765M |
| October 23, 2026 | 5.262M |
| October 22, 2026 | 6.460M |
| October 21, 2026 | 4.564M |
| October 20, 2026 | 4.663M |
| October 19, 2026 | 4.863M |
| Date | Value |
|---|---|
| October 16, 2026 | 8.356M |
| October 15, 2026 | 5.761M |
| October 14, 2026 | 7.058M |
| October 13, 2026 | 4.863M |
| October 12, 2026 | 3.154M |
| October 09, 2026 | 3.666M |
| October 08, 2026 | 3.466M |
| October 07, 2026 | 3.865M |
| October 06, 2026 | 3.765M |
| October 05, 2026 | 3.765M |
| October 02, 2026 | 2.668M |
| October 01, 2026 | 1.969M |
| September 30, 2026 | -1.224M |
| September 29, 2026 | -6.345M |
| September 28, 2026 | -6.645M |
| September 25, 2026 | -7.243M |
| September 24, 2026 | -5.746M |
| September 23, 2026 | -4.449M |
| September 22, 2026 | -3.651M |
| September 21, 2026 | -3.751M |
| September 18, 2026 | -4.05M |
| September 17, 2026 | -2.254M |
| September 16, 2026 | -2.054M |
| September 15, 2026 | -2.553M |
| September 14, 2026 | -1.455M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
| Arrowhead Pharmaceuticals, Inc. | 6.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.638M |
| Total Expenses (Quarterly) | 5.638M |
| EPS Diluted (Quarterly) | -0.5644 |
| Earnings Yield | -244.5% |
| Normalized Earnings Yield | -244.50 |